Investigational drug · Phase 3
Prevenar 20
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Healthy.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
111
Any phase or sponsor naming "Prevenar 20"
First trial start
2025
Aug 25, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Prevenar 20", any sponsor or status.
Conditions studied
As listed on its trial records.
- Healthy
Largest trials
Live from ClinicalTrials.gov: studies naming "Prevenar 20" as an intervention, largest first.
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their BabiesPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07160244 · 6,000 participants (planned) · Start Aug 25, 2025 · Primary completion Nov 6, 2028
Drug: Multivalent Group B streptococcus vaccine; Placebo and 5 more · For: Healthy
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 219 sites in all
- A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to AdultsPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT07794748 · 4,701 participants · Start Sep 8, 2026 · Primary completion Apr 26, 2027
Drug: PG4 Multivalent Vaccine; PG4 Multivalent Vaccine and 2 more · For: Pneumococcal Disease
Sites: Birmingham, Alabama; Lake Forest, California; Walnut Creek, California · 37 sites in all
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49Pivotal-lookingCompleted
Vaxcyte, Inc.Industry
NCT07284654 · 4,049 participants · Start Dec 1, 2025 · Primary completion Sep 17, 2026
Drug: 31 valent pneumococcal conjugate vaccine; PCV20 and 1 more · For: Pneumococcal Disease
Sites: Birmingham, Alabama; Chinle, Arizona; Whiteriver, Arizona · 30 sites in all
- Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve AdultsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03760146 · 3,902 participants · Start Dec 12, 2018 · Primary completion Dec 16, 2019
Drug: 20vPnC; 13vPnC and 1 more · For: Pneumococcal Disease
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 68 sites in all
- A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07629440 · 3,230 participants (planned) · Start May 29, 2026 · Primary completion Jun 5, 2029
Drug: PG4; 20-valent pneumococcal conjugate vaccine (20vPnC) · For: Pneumococcal Disease
Sites: Birmingham, Alabama; Fayetteville, Arkansas; Jonesboro, Arkansas · 134 sites in all
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05425732 · 2,663 participants · Start Jul 13, 2022 · Primary completion May 18, 2023
Drug: V116; PCV20 · For: Pneumococcal Infection
Sites: Birmingham, Alabama; Glendale, Arizona; Mesa, Arizona · 112 sites in all
- A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy InfantsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07573462 · 2,400 participants (planned) · Start May 4, 2026 · Primary completion Dec 30, 2028
Drug: PG4; 20-valent pneumococcal conjugate vaccine (20vPnC) · For: Pneumococcal Disease
Sites: Estero, Florida; Fort Lauderdale, Florida; Fort Myers, Florida · 91 sites in all
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06824194 · 2,360 participants · Start Feb 18, 2025 · Primary completion Oct 22, 2027
Drug: PCV21 vaccine; Prevnar 20 vaccine and 8 more · For: Pneumococcal Immunization
Sites: Birmingham, Alabama; Guntersville, Alabama; Oneonta, Alabama · 132 sites in all
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and ToddlersPivotal-lookingTerminated
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06397768 · 2,226 participants · Start May 13, 2024 · Primary completion Sep 18, 2025
Drug: RSVt vaccine; Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine and 7 more · For: RSV Immunization
Sites: Birmingham, Alabama; Grand Bay, Alabama; Mobile, Alabama · 72 sites in all
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of AgePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07348692 · 2,195 participants (planned) · Start Jan 20, 2026 · Primary completion Jun 7, 2027
Drug: PCV21 vaccine; 20vPCV licensed vaccine · For: Pneumococcal Immunization; Healthy Volunteers
Sites: Fayetteville, Arkansas; Huntington Park, California; Los Angeles, California · 25 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Healthy
- DTap-HepB-IPV-Hib vaccineHexyon, Infanrix hexaPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization
- V181Phase 31 trial
Merck & Co. · Healthy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.